The conversation highlights the historical dominance of pharma in biotech investments, with a recognition that new applications, especially in climate solutions, are emerging. Arye discusses the challenges faced by biotech in commodity markets, particularly in biofuels, while noting a shift in consumer willingness to pay a premium for carbon-neutral products. This evolving demand could reshape the future of biotech applications in various sectors.
